Evidence map›Paper›PMID 31011660›Full record

ArticleContemporary clinical trials communications2019

Single arm phase II trial assessing the safety, compliance with and activity of Bezafibrate and medroxyProgesterone acetate (BaP) therapy against myeloid and lymphoid cancers.

Jim Murray, Guy Pratt, Abe Jacob, Fiona Clark, Rachel Blundred, Sonia Fox, Rebecca Bishop, Keith Wheatley, Farhat Khanim, Chris Bunce and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Contemporary clinical trials communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

Jim MurrayQueen Elizabeth Hospital Birmingham, University Hospital Birmingham NHS Foundation Trust, UK.
Guy PrattHeartlands Hospital, University Hospital Birmingham NHS Foundation Trust, UK.
Abe JacobNew Cross Hospital, The Royal Wolverhampton Hospitals Trust, UK.
Fiona ClarkWorcestershire Royal Hospital, Worcestershire Acute Hospitals NHS Trust, UK.
Rachel BlundredCancer Research UK Clinical Trials Unit, Birmingham, UK.
Sonia FoxCancer Research UK Clinical Trials Unit, Birmingham, UK.
Rebecca BishopCancer Research UK Clinical Trials Unit, Birmingham, UK.
Keith WheatleyCancer Research UK Clinical Trials Unit, Birmingham, UK.
Farhat KhanimSchool of Biosciences, University of Birmingham, UK.
Chris BunceSchool of Biosciences, University of Birmingham, UK.
Mark DraysonInstitute of Immunology and Immunotherapy, University of Birmingham, UK.
Cancer Research UK Clinical Trials Unit · GBUniversity of Birmingham · GBHeartlands Hospital · GBUniversity Hospitals Birmingham NHS Foundation Trust · GBWolverhampton Hospital · GBWorcestershire Acute Hospitals NHS Trust · GB

Funding

Cancer Research UK 25354
6 · The paper itself

Abstract

We previously reported the safety and efficacy of low dose BaP [

Indexed as

BezafibrateClinical trialsLymphoid malignanciesMyeloid leukaemiaProgesteroneTherapy

Identifiers

PMID31011660
PMCPMC6463739
OpenAlexW2940035719

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.